deltatrials
Terminated PHASE2 NCT00448682

Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery

A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065)

Sponsor: University of Miami

Conditions Gastric Cancer
Interventions Docetaxel Floxuridine Leucovorin Oxaliplatin
Updated 9 times since 2017 Last updated: Dec 14, 2016 Started: Jun 30, 2005 Primary completion: Dec 31, 2009 Completion: Mar 31, 2010

Listed as NCT00448682, this PHASE2 trial focuses on Gastric Cancer and remains terminated or withdrawn. Sponsored by University of Miami, it has been updated 9 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Miami
Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Miami, United States